| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE OF SEGMENT INFORMATION
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the Three Months Ended
July 31, |
|
|
For the Nine Months Ended
July 31, |
|
| |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
| Net loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,145 |
) |
|
$ |
(1,091 |
) |
|
$ |
(4,115 |
) |
|
$ |
(2,999 |
) |
| Cancer Vaccines |
|
|
(2,160 |
) |
|
|
(1,390 |
) |
|
|
(5,628 |
) |
|
|
(3,261 |
) |
| Other |
|
|
(10 |
) |
|
|
(67 |
) |
|
|
(42 |
) |
|
|
(949 |
) |
| Total |
|
$ |
(3,315 |
) |
|
$ |
(2,548 |
) |
|
$ |
(9,785 |
) |
|
$ |
(7,209 |
) |
| Net income/(loss) |
|
$ |
(3,315 |
) |
|
$ |
(2,548 |
) |
|
$ |
(9,785 |
) |
|
$ |
(7,209 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
3,592 |
|
|
$ |
2,844 |
|
|
$ |
10,668 |
|
|
$ |
8,170 |
|
| Less non-cash stock-based compensation |
|
|
(1,179 |
) |
|
|
(1,217 |
) |
|
|
(3,699 |
) |
|
|
(3,507 |
) |
| Operating costs and expenses excluding non-cash stock-based compensation |
|
$ |
2,413 |
|
|
$ |
1,627 |
|
|
$ |
6,969 |
|
|
$ |
4,663 |
|
| Operating costs and expenses excluding non-cash stock-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
789 |
|
|
$ |
713 |
|
|
$ |
2,943 |
|
|
$ |
1,930 |
|
| Cancer Vaccines |
|
|
1,614 |
|
|
|
855 |
|
|
|
3,988 |
|
|
|
1,966 |
|
| Other |
|
|
10 |
|
|
|
59 |
|
|
|
38 |
|
|
|
767 |
|
| Total |
|
$ |
2,413 |
|
|
$ |
1,627 |
|
|
$ |
6,969 |
|
|
$ |
4,663 |
|
| Operating
costs and expenses excluding non-cash stock-based compensation |
|
$ |
2,413 |
|
|
$ |
1,627 |
|
|
$ |
6,969 |
|
|
$ |
4,663 |
|
| |
|
July 31,
2024 |
|
|
October 31,
2023 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
7,493 |
|
|
$ |
7,523 |
|
| Cancer Vaccines |
|
|
15,290 |
|
|
|
17,215 |
|
| Other |
|
|
125 |
|
|
|
784 |
|
| Total |
|
$ |
22,908 |
|
|
$ |
25,522 |
|
| Total
assets |
|
$ |
22,908 |
|
|
$ |
25,522 |
|
|